Understanding how to improve CAR T cell treatments for large B cell lymphoma patients

Learning features of optimal CAR T cells for LBCL from patient data

NIH-funded research Stanford University · NIH-11256827

This study is looking at how well CAR T cell therapies work for people with large B cell lymphoma, aiming to find the best types of these treatments and understand why some patients might not respond as well, so we can improve outcomes for everyone.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionStanford University NIH-funded
Lab location1 site (Stanford, United States)
Project IDNIH-11256827 on NIH RePORTER

What this research studies

This research investigates the effectiveness of CAR T cell therapies specifically for patients with large B cell lymphoma (LBCL). By analyzing patient data, the study aims to identify the most effective CAR T cell subsets and understand the mechanisms that lead to treatment resistance. The approach combines experimental techniques with computational analysis to uncover insights that could enhance the efficacy of these immunotherapies. Patients may have their individual responses to CAR T cell therapy evaluated, contributing to a broader understanding of treatment outcomes.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients diagnosed with large B cell lymphoma who are considering or undergoing CAR T cell therapy.

Not a fit: Patients with other types of cancers or those who do not have large B cell lymphoma may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective CAR T cell therapies, improving treatment outcomes for patients with large B cell lymphoma.

How similar studies have performed: Previous research has shown promising results in enhancing CAR T cell therapies, indicating that this approach has the potential for significant advancements.

Where this research is happening

Stanford, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-cancer immunotherapyanticancer immunotherapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.